Tải xuống
Tóm tắt
Neuroblastoma (NBL) is the most common extracranial solid cancer of childhood and is characterized by a remarkable biological heterogeneity, resulting in favorable or unfavorable outcomes. There are many prognostic factors like age, stage, histopathology, plasma and urinary markers and the molecular characteristics of tumor cells. Amplification of the MYCN gene (MYCNA) is established as the most powerful prognostic factor. This study aimed to investigate, in a series of 131 NBL patients ascertained from 2013 to 2015, the relationship between amplification of MYCN and some other prognostic factors: patient's age, histopathology, VMA/HVA ratio and LDH level. MYCNA was identified by FISH and the MYCN status was compared with the other clinic-biological factors. As a result, MYCNA was found on 27/131 NBL patients. The number of MYCNA according to the age group was 9/27 cases below12 months, 4/27 cases 12- 18 months and 14/27 cases over 18 months. The favorable and unfavorable histology cases showed a different frequency of MYCNA, 11/24 cases and 13/24 cases, respectively. 20/21 patients with MYCNA have a VMA/HVA ratio below 1, and 17/24 cases of them had LDH level above three times than normal level (both associated with worse prognosis). Therefore, the MYCNA is strongly associated with age at diagnosis >18 months, unfavorable histology, VMA/HVA ratio below 1 and high LDH level. The VMA/HVA ratio and LDH level could be valuable markers for diagnosis and monitoring of disease status, however, the MYCN status determined by FISH is one of the most important tools for treatment stratification.
Tài liệu tham khảo
Thorner, P.S., The molecular genetic profile of neuroblastoma. Diagnostic Histopathology, 2014. 20(2): p. 76-83.
Maris, J.M., Recent Advances in Neuroblastoma. The New England Journal of Medicine, 2010. 362(23): p. 2202-2211.
Evans, A.E. and G.J. D’Angio, Age at diagnosis and prognosis in children with neuroblastoma. Journal of Clinical Oncology, 2005. 23(27): p. 6443-4.
Cohn, S.L., et al., The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol, 2009. 27(2): p. 289-97.
Burgues, O., et al., Prognostic value of the International Neuroblastoma Pathology Classification in Neuroblastoma (Schwannian stroma-poor) and comparison with other prognostic factors: a study of 182 cases from the Spanish Neuroblastoma Registry. Virchows Arch, 2006. 449(4): p. 410-20.
Cangemi, G., et al., Prognostic value of ferritin, neuron-specific enolase, lactate dehydrogenase, and urinary and plasmatic catecholamine metabolites in children with neuroblastoma. OncoTargets and therapy, 2012. 5: p. 417-23.
Trần, T.C.M., T.H. Nguyễn, and T.L. Phùng, Giá trị của HVA-VMA trong chẩn đoán u nguyên bào thần kinh. Tạp chí nghiên cứu y học, 2014. 89(4): p. 15-22.
Pedram, M., et al., Impact of N-myc Amplification on Median Survival in Children With Neuroblastoma. Journal of Comprehensive Pediatrics, 2012. 3(1): p. 29-33.
George, R.E., et al., Relationship Between Histopathological features, MYCN Amplification, and Prognosis: A UKCCSG Study. Medical and Pediatric Oncology, 2001. 36: p. 169–176.
Zambrano, E. and M. Reyes-Mugica, Hormonal activity may predict aggressive behavior in neuroblastoma. Pediatric and developmental pathology, 2002. 5(2): p. 190-9.
| Đã xuất bản | 19-08-2016 | |
| Toàn văn |
|
|
| Ngôn ngữ |
|
|
| Số tạp chí | Số 36 (2016) | |
| Phân mục | Nghiên cứu | |
| DOI | ||
| Từ khóa | Neuroblastoma, MYCN, MYCN amplification, age at diagnosis, histopathology, biochemistry parameters |
công trình này được cấp phép theo Creative Commons Attribution-phi thương mại-NoDerivatives 4.0 License International .
Bản quyền (c) 2025 Tạp chí Y học lâm sàng Bệnh viện Trung Ương Huế